Israel-based Redhill BioPharma says six coronavirus patients treated with its anti-inflammatory drug opaganib have shown marked improvement, and five have been able to be weaned off of oxygen.
Three of the patients have already been released from hospitals, it says.
The drug was approved earlier this month for compassionate use in Israel and Italy.
“Preliminary findings from all six patients analyzed have shown that all the patients demonstrated objective significant measurable clinical improvement within days following treatment initiation with opaganib,” the firm says in a statement. “Opaganib was well tolerated and showed clinical improvement both with and without hydroxychloroquine.”
It says it has asked the FDA for an okay to move ahead with a trial in the US and is kicking off clinical trials in Israel and Italy.
Redhill’s stock is up over 11 percent in after-hours trading.
Help us report truthfully on social media
As a multimedia journalist, my job is to take the quality, fact-based journalism produced by The Times of Israel newsroom and make it accessible across every platform — from Instagram posts to podcasts to short-form videos.
This is how many, especially young people, consume news these days. But misinformation is rampant on social media. Our team at ToI produces accurate, responsible short-form reporting on Israel and the Jewish world.
If you believe in the importance of factual social media journalism, please consider joining our reader support group, The Times of Israel Community. Your financial support is essential to sustain responsible multimedia reporting.
— Gabriella Jacobs, multimedia journalist
Support our work
Support our work
Already a member? Sign in to stop seeing this
You're a dedicated reader
We’re really pleased that you’ve read X Times of Israel articles in the past month.
That’s why we started the Times of Israel - to provide discerning readers like you with must-read coverage of Israel and the Jewish world.
So now we have a request. Unlike other news outlets, we haven’t put up a paywall. But as the journalism we do is costly, we invite readers for whom The Times of Israel has become important to help support our work by joining The Times of Israel Community.
For as little as $6 a month you can help support our quality journalism while enjoying The Times of Israel AD-FREE, as well as accessing exclusive content available only to Times of Israel Community members.
Thank you,
David Horovitz, Founding Editor of The Times of Israel
Join Our Community
Join Our Community
Already a member? Sign in to stop seeing this
From the Liveblog of
Monday, April 27, 2020
Add ToI as a Preferred Source on Google
